In the phase II DESTINY-Lung01 study, trastuzumab deruxtecan was also evaluated in HER2-overexpressed metastatic NSCLC (IHC 2+ and 3+) at two dose levels: 6.4 and 5.4 mg/kg. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.